Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-18FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for Rhodes Pharmaceuticals L.P. for a four-ingredient amphetamine product (dextroamphetamine sacchar…
-
FDA approval · 2023-10-17FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Amphetamine sulfate from Granules Pharmaceuticals Inc. to support a formulation change to a gran…
-
FDA approval · 2023-10-17FDA Approved: GUANFACINE — Original Application (Advagen Pharma Ltd)
FDA approves Advagen Pharma Ltd's generic guanfacine as an approved product under ANDA 216762, confirming it as a generic version of guanfac…
-
FDA approval · 2023-10-16FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for amphetamine sulfate (Amneal Pharmaceuticals NY LLC), resulting in an updated regulatory approval…
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for a four-salt combination product containing dextroamphetamine saccharate…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-10-13FDA Approved: APTENSIO XR — Supplemental Application (Rhodes Pharmaceuticals L.P.)
FDA approved a supplemental application for Aptensio XR (methylphenidate hydrochloride) from Rhodes Pharmaceuticals L.P., approving changes …
-
FDA approval · 2023-10-13FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) by Sandoz Inc.
-
FDA approval · 2023-10-13FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
FDA approved a supplemental application for METHYLIN (methylphenidate hydrochloride) from Shionogi Inc., potentially updating the label or i…
-
FDA approval · 2023-10-13FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
FDA approves a supplemental application for methylphenidate hydrochloride CD from Lannett Company, Inc. under NDA 021259.
-
FDA approval · 2023-10-13FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN (dexmethylphenidate hydrochloride) submitted by Sandoz Inc., adding to the product's…
-
FDA approval · 2023-10-13FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for methylphenidate (Sandoz Inc) to update the product labeling under the NDA.
-
FDA approval · 2023-10-13FDA Approved: RITALIN — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for RITALIN (methylphenidate hydrochloride) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-10-13FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, indicating an…
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for dextroamphetamine sulfate (generic).
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application by Teva for a four-salt amphetamine product consisting of dextroamphetamine saccharate, amphetamine …
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Epic Pharma, LLC)
FDA approves Epic Pharma, LLC's supplemental application for a generic product containing dextroamphetamine saccharate, amphetamine aspartat…
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application from Sandoz Inc for a generic combination product containing four amphetamine salts (dextroamphetami…
-
FDA approval · 2023-10-13FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for DYANAVEL XR (amphetamine) filed by NextWave Pharmaceuticals, Inc.
-
FDA approval · 2023-10-13FDA Approved: QUILLICHEW ER — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for Quillichew ER (methylphenidate hydrochloride) from NextWave Pharmaceuticals. The action upda…
-
FDA approval · 2023-10-13FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Supplemental Application (Neos Therapeutics, LP)
The FDA approved a supplemental application for an extended-release formulation of amphetamine from Neos Therapeutics, LP.
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Lupin Pharmaceuticals,Inc.)
FDA approved a supplemental application for a generic dextr oamphetamine sulfate product from Lupin Pharmaceuticals, authorizing its continu…
-
FDA approval · 2023-10-13FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride from Rising Pharma Holdings, Inc., authorizing its continued marke…
-
FDA approval · 2023-10-13FDA Approved: COTEMPLA XR-ODT — Supplemental Application (Neos Therapeutics Brands, LLC)
The FDA approved a supplemental application for Cotempla XR-ODT (methylphenidate) from Neos Therapeutics Brands, LLC.
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (SUNRISE PHARMACEUTICAL, INC.)
The FDA approved a supplemental application for dextroamphetamine sulfate submitted by Sunrise Pharmaceutical, Inc.
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (SUNRISE PHARMACEUTICAL, INC.)
The FDA approved Sunrise Pharmaceutical's supplemental application for a four-salt amphetamine product (dextroamphetamine saccharate, amphet…